Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay

Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes Exelixis' zanzalintinib and Roche's (RHHBY) Tecentriq. William Blair analyst Andy Hsieh says it's unlikely the agency will outright reject the combo, which showed an overall survival benefit for…